Improving cardiovascular disease management in Australia: NPS MedicineWise

Medical Journal of Australia

Volumn 199, Issue 3, 2013, Pages 192-195

  Gadzhanova, Svetla V ^a   Roughead, Elizabeth E ^a   Bartlett, Mark J ^b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b NPS MedicineWise   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; SPIRONOLACTONE; WARFARIN;

AGED; ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG USE; ECHOCARDIOGRAPHY; FEMALE; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; INTERVENTION STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIMARY HEALTH CARE; SECONDARY PREVENTION; TIME SERIES ANALYSIS;

ADULT; AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; AUSTRALIA; CARDIOVASCULAR DISEASES; DATABASES, FACTUAL; DISEASE MANAGEMENT; DRUG UTILIZATION; FEMALE; HUMANS; INTERVENTION STUDIES; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PRIMARY HEALTH CARE; PROGRAM EVALUATION; QUALITY IMPROVEMENT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WARFARIN;

EID: 84881281395     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja12.11779     Document Type: Article

References (21)

1. Australian Institute of Health and Welfare. Australia's health 2010. Canberra: AIHW, 2010. (AIHW Cat. No. AUS 122; Australia's Health No. 12.) http://www.aihw.gov.au/publication-detail/?id=6442468376 (accessed Jun 2013).
2. National Prescribing Service Limited. Using antithrombotics: maximising benefits; minimising risks. Prescribing Practice Review 24; Dec 2003. http://www.nps.org.au/__data/assets/pdf_file/ 0008/16955/ppr24.pdf (accessed Jun 2013).
3. National Prescribing Service Limited. Antiplatelet and anticoagulant therapy in stroke prevention. Prescribing Practice Review 44; Mar 2009. http://www.nps.org.au/__data/assets/pdf_file/0008/ 68813/PPR44_Anticoagulants_0309.pdf (accessed Jun 2013).
4. National Prescribing Service Limited. Medication review for your patients with heart failure. Prescribing Practice Review 8; May 2000. http://www.nps.org.au/__data/assets/pdf_file/0003/ 16923/ppr08.pdf (accessed Jun 2013).
5. National Prescribing Service Limited. Improving outcomes for heart failure patients. Prescribing Practice Review 28; Nov 2004. http://www.nps.org.au/__data/assets/pdf_file/0007/16963/ ppr28.pdf (accessed Jun 2013).
6. National Prescribing Service Limited. Improving outcomes in chronic heart failure. Prescribing Practice Review 41; May 2008. http://www.nps.org.au/__data/assets/pdf_file/0008/35495/PPR41_Improving_outcomes_chronic_heart_failure_0508.pdf (accessed Jun 2013).
7. O' Brien MA, Rogers S, Jamtvedt G, et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2007; (4): CD000409.
8. Australian Government Department of Veterans' Affairs. Veterans' Medicines Advice and Therapeutics Education Services (Veterans' MATES). http://www.veteransmates.net.au (accessed Nov 2012).
9. Australian Government Department of Veterans' Affairs. The SAFE approach to warfarin therapy. Veterans' MATES Therapeutic brief 17; Nov 2008. http://www.veteransmates.net.au/VeteransMATES/documents/module_materials/ M17_TherBrief.pdf (accessed Jun 2013).
10. Australi an Government Department of Veterans' Affairs. Treatment population statistics December 2011. Canberra: DVA, 2011. http://www.dva.gov.au/aboutDVA/Statistics/Documents/TpopDec2011.pdf (accessed Jun 2013).
11. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regressing analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002; 27: 299-309.
12. Zimetbaum PJ, Thosani A, Yu HT, et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med 2010; 123: 446-453.
13. Acelajado MC, Oparil S. Antiplatelet therapy for transient ischemic attack. J Clin Hypertens (Greenwich) 2012; 14: 103-111.
14. Neurology Expert Group. Therapeutic guidelines: neurology. Version 3. Melbourne: Therapeutic Guidelines Limited, 2008.
15. Abhayaratna WP, Smith WT, Becker NG, et al. Prevalence of heart failure and systolic venticular dysfunction in older Australians: the Canberra Heart Study. Med J Aust 2006; 184: 151-154.
16. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Guidelines for the prevention, detection and management of chronic heart failure in Australia. Updated October 2011. http://www.heartfoundation.org.au/information-for-professionals/Clinical-Information/Pages/heart-failure.aspx (accessed Jun 2013).
17. Scottish Intercollegiate Guidelines Network. Management of chronic heart failure: a national clinical guideline. SIGN Guideline No. 95, 2007. www.sign.ac.uk/pdf/sign95.pdf (accessed Jun 2013).
18. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
19. Pont LG, Sturkenboom MC, van Gilst WH, et al. Trends in prescribing for heart failure in Dutch primary care from 1996 to 2000. Pharmacoepidemiol Drug Saf 2003; 12: 327-334.
20. Oxman DA, Thomson MA, Davis DA, Haynes RB. No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. CMAJ 1995; 153: 1423-1431.
21. Lloyd J, Anderson P. Veterans's use of health serv ices. Canberra: Australian Institute of Health and Welfare, 2008. (AIHW Cat. No. AGE 51.) http://www.aihw.gov.au/publication-detail/?id=6442468071 (accessed Jun 2013).